[1]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
|
[2]National Health and Family Planning Commission of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J].J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.
|
[3]ZENG MS, YE HY, GUO L, et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients:a multicenter, open-label, phase III study[J].Hepatobiliary Pancreat Dis Int, 2013, 12 (6) :607-616.
|
[4]ZHOU LY, ZENG ZC, FAN J, et al.Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma:clinical features and prognostic factors[J].BMC Cancer, 2014, 14:878-886.
|